Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Metastatic colorectal cancer (mCRC) remains a lethal disease with an approximately 14% 5-
year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with …

Recent progress in targeting KRASG12C has provided both insight and inspiration for
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …

Liver metastasis, the leading cause of colorectal cancer mortality, exhibits a highly
heterogeneous and suppressive immune microenvironment. Here, we sequenced 97 …

Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …

PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF …

Colorectal cancer has served as a genetic and biological paradigm for the evolution of solid
tumors, and these insights have illuminated early detection, risk stratification, prevention …

Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …

Importance For patients withRASwild-type metastatic colorectal cancer, adding anti–
epidermal growth factor receptor (anti-EGFR) or anti–vascular endothelial growth factor (anti …

Mutation-induced activation of WNT–β-catenin signalling is a frequent driver event in human
cancer. Sustained WNT–β-catenin pathway activation endows cancer cells with sustained …